280 East Grand Avenue
South San Francisco
414 articles with Cytokinetics, Inc.
Despite not hitting endpoints, Cytokinetics noted that the FORTITUDE-ALS trial demonstrated consistency of effect for doses, endpoints and timepoints.
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes
Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Amgen (NASDAQ: AMGN),Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment.
Cytokinetics, Incorporated today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City.
Gamida Cell Ltd. filed for a $69 million initial public offering for the Nasdaq exchange, according to a filing submitted last week to the U.S. Securities and Exchange Commission, Israel’s Calcalist first reported last week.
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable...
Results from Phase 2 Clinical Trial of Reldesemtiv in Patients with COPD Expected in Q3
Cytokinetics, Incorporated announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time.
Cytokinetics released data from its Phase II clinical trial of reldesemtiv in patients with spinal muscular atrophy (SMA).
Califf is also serving as an advisor to the senior management team at Verily Life Sciences.
Results from four clinical trials of CK-2127107 expected in 2018.
Cytokinetic's New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS
The results showed that CK-2127107 increased the force generated by the tibialis anterior muscle versus placebo in response to nerve stimulation in a dose, plasma concentration, and frequency-dependent manner.
Cytokinetics has suspended development of tirasemtiv after it failed to differentiate itself from placebo in a statistically significant manner.
Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017
The data was presented by John Teerlink, M.D. in an Abstract Rapid Fire Oral presentation at the American Heart Association Scientific Sessions 2017 in Anaheim, Calif.
The company reported total revenues for the third quarter of 2017 were $6.2 million, compared to $59.0 million, during the same period in 2016.
Cytokinetics Announces Dosing Of First Patient In Japan In GALACTIC-HF, Phase III Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
Cytokinetics Announces Presentation Of Additional Results From COSMIC-HF At The HFSA 21st Annual Scientific Meeting
Cytokinetics Announces Additional Results From COSMIC-HF To Be Presented At The HFSA 21st Annual Scientific Meeting